Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

Susan Dutton(Nuffield Orthopaedic Centre), David Ferry(The Royal Wolverhampton NHS Trust), Jane Blazeby(University Hospitals Bristol NHS Foundation Trust), Haider Abbas(The Royal Wolverhampton NHS Trust), Åsa Dahle-Smith(University of Aberdeen), Wasat Mansoor(The Christie NHS Foundation Trust), Joyce Thompson(Heartlands Hospital), Mark Harrison(Mount Vernon Cancer Centre), Anirban Chatterjee(Royal Shrewsbury Hospital), Stephen Falk(University Hospitals Bristol NHS Foundation Trust), Angel Garcia-Alonso(Glan Clwyd Hospital), D. Fyfe(Furness General Hospital), Richard Hubner(The Christie NHS Foundation Trust), Tina Gamble(Heartlands Hospital), Lynnda Peachey(University of Oxford), Mina Davoudianfar(University of Oxford), Sarah Pearson(University of Oxford), Patrick Julier(University of Oxford), Janusz Jankowski(Coventry University), Rachel Kerr(University of Oxford), Russell Petty(University of Aberdeen)
The Lancet Oncology
June 17, 2014
Cited by 330Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis